Pharmacologic Reperfusion Therapy with Indigenous Tenecteplase in 15,222 patients with ST Elevation Myocardial Infarction – The Indian Registry

Pharmacologic Reperfusion Therapy with Indigenous Tenecteplase in 15,222 patients with ST Elevation Myocardial Infarction – The Indian Registry

Objective: To study the efficacy and safety of single intravenous bolus administration of indigenously developed tenecteplase (TNK-tPA) in the management of patients with ST-elevation myocardial infarction (STEMI) in clinical practice. Methods: Observational, prescription-event monitoring study. Res...

Full description

Bibliographic Details
Main Authors:	S.S. Iyengar, T. Nair, J.S. Hiremath, U. Jadhav, V.K. Katyal, D. Kumbla, I. Sathyamurthy, R.K. Jain, M. Srinivasan
Format:	Article
Language:	English
Published:	Elsevier 2013-07-01
Series:	Indian Heart Journal
Subjects:	Tenecteplase STEMI Prescription-event monitoring
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483213001909

Similar Items

Evaluation of the tolerability and effectiveness of Tenecteplase in patients with ST-Segment-Elevation Myocardial Infarction in a Secondary Hospital in Malaysia: A Retrospective Case Series
by: Kin Wei Chua, MSc,Med(ClinEpi), et al.
Published: (2021-01-01)

Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset
by: Mahesh Kate, et al.
Published: (2018-01-01)

Preintensive care: Thrombolytic (streptokinase or tenecteplase) in ST elevated acute myocardial infarction at peripheral hospital
by: Himmatrao S Bawaskar, et al.
Published: (2019-01-01)

TENECTEPLASE AS A NEW MEDICATION IN MANAGING NO-REFLOW
by: Milan Živković, et al.
Published: (2012-03-01)

Comparative Study of Two Tenecteplase Therapeutic Protein Purification Methods
by: Hossein Javid
Published: (2021-09-01)

Creation of Tenecteplase-Producing CHO Cell Line Using Site-Specific Integrase from the Phage φC31
by: Khadijeh Karbalaie, et al.
Published: (2010-01-01)

Successful use of Tenecteplase in a patient with recurrence of prosthetic mitral valve thrombosis
by: Harshal A. Lahoti, et al.
Published: (2015-12-01)

CLINICAL RESULTS OF THROMBOLYTIC THERAPY WITH ALTEPLASE AND TENECTEPLASE IN PATIENTS WITH MYOCARDIAL INFARCTION
by: L. A. Bondarenko, et al.
Published: (2015-12-01)

Tenecteplase Thrombolysis in Posterior Circulation Stroke
by: Fana Alemseged, et al.
Published: (2021-08-01)

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA
by: Tobias Frühwald, et al.
Published: (2019-08-01)

Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse®) with those of an alleged biosimilar
by: Werner eKliche, et al.
Published: (2014-02-01)

Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand
by: Chaiyakunapruk, N., et al.
Published: (2022)

Letter to the Editor for sponsored article “Pharmacologic reperfusion therapy with indigenous tenecteplase in 15,222 patients with ST elevation myocardial infarction – the Indian registry” by Iyengar et al
by: Nicolas Danchin
Published: (2014-03-01)

COST-EFFECTIVENESS EVALUATION OF PREHOSPITAL THROMBOLYSIS WITH TENECTEPLASE
by: V. V. Omel'yanovskiy, et al.
Published: (2016-01-01)

Intrapleural Tenecteplase Therapy in Treatment of Loculated Parapneumonic Pleural Effusions and Empyema
by: Alaa Refaat, et al.
Published: (2014-10-01)

Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
by: G. Ravi Kiran, et al.
Published: (2021-05-01)

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
by: Xu N, et al.
Published: (2018-07-01)

Clinical profile and mortality of ST-Segment elevation myocardial- infarction patients receiving thrombolytic -Therapy in the Middle East
by: Prashanth Panduranga, et al.
Published: (2012-01-01)

Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement
by: Charithani B. Keragala, et al.
Published: (2020-12-01)

COMPARATIVE RESULTS OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE AND TENECTEPLASE USE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN REAL CLINICAL PRACTICE
by: E. S. Mazur, et al.
Published: (2017-09-01)

Systemic Thrombolytic Therapy for Pulmonary Embolism in Early Postoperative Period Following Laparoscopic Vaginal Hysterectomy
by: BV Sunil, et al.
Published: (2019-01-01)

Plasminogen activators in acute management of thrombosis
by: E. O. Taratukhin
Published: (2013-06-01)

Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario
by: Jamshed Dalal, et al.
Published: (2013-09-01)

Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989–2018): The Ruti-STEMI-Shock Registry
by: Cosme García-García, et al.
Published: (2020-07-01)

Clinical Characteristics, Treatments, and Outcomes of Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Results from a Multicenter National Registry
by: Pawel Gasior, et al.
Published: (2020-08-01)

Achieving the earliest possible reperfusion in patients with acute coronary syndrome: a current overview
by: Takahiro Nakashima, et al.
Published: (2018-03-01)

Effect of a Government Scheme on Reperfusion Trends in a tertiary care centre in South India
by: Paul V. George, et al.
Published: (2014-09-01)

Hyperglycaemia, adverse outcomes and impact of intravenous insulin therapy in patients presenting with acute ST‐elevation myocardial infarction in a socioeconomically disadvantaged urban setting: The Montefiore STEMI Registry
by: Sanyog G. Shitole, et al.
Published: (2020-01-01)

Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
by: S. A. Naumov, et al.
Published: (2018-09-01)

Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury
by: Marina Rieder, et al.
Published: (2020-09-01)

RISKS AND BENEFITS OF REPERFUSION STRATEGIES IN ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION
by: T. M. Poponina, et al.
Published: (2010-10-01)

Procedural and clinical benefits of selective thrombus aspiration in primary PCI. Insights from the TAPER Registry
by: Alfonso Jurado-Román, et al.
Published: (2019-08-01)

Innovations in acute stroke reperfusion strategies
by: Venugopalan Y Vishnu, et al.
Published: (2019-01-01)

Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a “real world” STEMI population: results from the Italian “CARDIO-STEMI SANREMO” registry
by: Federico Sanchez, et al.
Published: (2021-03-01)

THE RELEVANCE OF THROMBOLYTIC THERAPY IN ST ELEVATION MYOCARDIAL INFARCTION
by: N. V. Teplova, et al.
Published: (2014-05-01)

New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
by: María Asunción Esteve-Pastor, et al.
Published: (2016-02-01)

Value of modified selvester QRS score in prediction of successful reperfusion in patients with acute myocardial infarction
by: Mohammad M Al-Daydamony, et al.
Published: (2014-03-01)

CURRENT REPERFUSION THERAPY POSSIBILITIES IN MYOCARDIAL INFARCTION AND ISCHEMIC STROKE
by: E. V. Konstantinova, et al.
Published: (2015-05-01)

Temporal trends in the pre-procedural TIMI flow grade among patients with ST- segment elevation myocardial infarction – From the ACSIS registry
by: Nili Schamroth Pravda, et al.
Published: (2021-10-01)

Health Technology Assessment of TNK-ase vs. Reteplase in the Treatment of Acute Myocardial Infarction in Iran
by: salman bashzar, et al.
Published: (2018-06-01)